FDA improperly denied Ranbaxy, Ivax rights to exclusivity

Share this article:
A federal judge ruled the FDA improperly denied generic drugmakers Ranbaxy and Ivax rights to 180 days of marketing exclusivity for generic forms of Merck's cholesterol-lowering drug Zocor (simvastatin). He threw out the FDA's decision to grant Merck's request to delist two patents.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.